These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 21962403

  • 1. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease.
    Urbonaviciene G, Martin-Ventura JL, Lindholt JS, Urbonavicius S, Moreno JA, Egido J, Blanco-Colio LM.
    Atherosclerosis; 2011 Dec; 219(2):892-9. PubMed ID: 21962403
    [Abstract] [Full Text] [Related]

  • 2. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio.
    Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, Martin-Ventura JL, Egido J, Gaussem P, Emmerich J, Michel JB, Blanco-Colio LM, Meilhac O.
    Arterioscler Thromb Vasc Biol; 2010 Jun; 30(6):1253-62. PubMed ID: 20299688
    [Abstract] [Full Text] [Related]

  • 3. Alterations of soluble TWEAK and CD163 concentrations in patients with chronic heart failure.
    Ptaszynska-Kopczynska K, Marcinkiewicz-Siemion M, Lisowska A, Waszkiewicz E, Witkowski M, Jasiewicz M, Miklasz P, Jakim P, Galar B, Musial WJ, Kaminski KA.
    Cytokine; 2016 Apr; 80():7-12. PubMed ID: 26916171
    [Abstract] [Full Text] [Related]

  • 4. The association of high sCD163/sTWEAK ratio with cardiovascular disease in hemodialysis patients.
    Rusu CC, Racasan S, Kacso IM, Ghervan L, Moldovan D, Potra A, Patiu IM, Bondor C, Caprioara MG.
    Int Urol Nephrol; 2015 Dec; 47(12):2023-30. PubMed ID: 26433887
    [Abstract] [Full Text] [Related]

  • 5. Serum sTWEAK concentrations and risk of developing type 2 diabetes in a high cardiovascular risk population: a nested case-control study.
    Díaz-López A, Chacón MR, Bulló M, Maymó-Masip E, Martínez-González MA, Estruch R, Vendrell J, Basora J, Díez-Espino J, Covas MI, Salas-Salvadó J.
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3482-90. PubMed ID: 23760626
    [Abstract] [Full Text] [Related]

  • 6. High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis.
    Kowal-Bielecka O, Bielecki M, Guiducci S, Trzcinska-Butkiewicz B, Michalska-Jakubus M, Matucci-Cerinic M, Brzosko M, Krasowska D, Chyczewski L, Kowal K.
    Arthritis Res Ther; 2013 Aug; 15(3):R69. PubMed ID: 23800379
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of sCD163 and sTWEAK in patients with stable peripheral arterial disease and association with disease severity as well as long-term mortality.
    Mrak D, Zierfuss B, Höbaus C, Herz CT, Pesau G, Schernthaner GH.
    Atherosclerosis; 2021 Jan; 317():41-46. PubMed ID: 33378730
    [Abstract] [Full Text] [Related]

  • 8. Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension.
    Jasiewicz M, Kowal K, Kowal-Bielecka O, Knapp M, Skiepko R, Bodzenta-Lukaszyk A, Sobkowicz B, Musial WJ, Kaminski KA.
    Cytokine; 2014 Mar; 66(1):40-5. PubMed ID: 24548423
    [Abstract] [Full Text] [Related]

  • 9. Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study.
    Llauradó G, González-Clemente JM, Maymó-Masip E, Subías D, Vendrell J, Chacón MR.
    PLoS One; 2012 Mar; 7(8):e43919. PubMed ID: 22937125
    [Abstract] [Full Text] [Related]

  • 10. Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD.
    Fernández-Laso V, Sastre C, Valdivielso JM, Betriu A, Fernández E, Egido J, Martín-Ventura JL, Blanco-Colio LM.
    Clin J Am Soc Nephrol; 2016 Mar 07; 11(3):413-22. PubMed ID: 26728587
    [Abstract] [Full Text] [Related]

  • 11. Markers of inflammation in relation to long-term cardiovascular mortality in patients with lower-extremity peripheral arterial disease.
    Urbonaviciene G, Frystyk J, Flyvbjerg A, Urbonavicius S, Henneberg EW, Lindholt JS.
    Int J Cardiol; 2012 Oct 04; 160(2):89-94. PubMed ID: 21463908
    [Abstract] [Full Text] [Related]

  • 12. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease.
    Valdivielso JM, Coll B, Martín-Ventura JL, Moreno JA, Egido J, Fernández E, Blanco-Colio LM.
    J Nephrol; 2013 Oct 04; 26(6):1105-13. PubMed ID: 23475462
    [Abstract] [Full Text] [Related]

  • 13. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis.
    Moreno JA, Muñoz-García B, Martín-Ventura JL, Madrigal-Matute J, Orbe J, Páramo JA, Ortega L, Egido J, Blanco-Colio LM.
    Atherosclerosis; 2009 Nov 04; 207(1):103-10. PubMed ID: 19473660
    [Abstract] [Full Text] [Related]

  • 14. Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.
    Beltrán LM, Muñoz Hernández R, de Pablo Bernal RS, García Morillo JS, Egido J, Noval ML, Ferrando-Martinez S, Blanco-Colio LM, Genebat M, Villar JR, Moreno-Luna R, Moreno JA.
    PLoS One; 2014 Nov 04; 9(3):e90541. PubMed ID: 24594990
    [Abstract] [Full Text] [Related]

  • 15. Reduced circulating levels of TWEAK are associated with gestational diabetes mellitus.
    Simón-Muela I, Llauradó G, Chacón MR, Olona M, Näf S, Maymó-Masip E, Gil P, de la Flor M, Gonzalez Clemente JM, Vendrell J, Megía A.
    Eur J Clin Invest; 2015 Jan 04; 45(1):27-35. PubMed ID: 25443800
    [Abstract] [Full Text] [Related]

  • 16. Serum sCD163 levels are associated with type 2 diabetes mellitus and are influenced by coffee and wine consumption: results of the Di@bet.es study.
    Rojo-Martínez G, Maymó-Masip E, Rodríguez MM, Solano E, Goday A, Soriguer F, Valdés S, Chaves FJ, Delgado E, Colomo N, Hernández P, Vendrell J, Chacón MR.
    PLoS One; 2014 Jan 04; 9(6):e101250. PubMed ID: 24978196
    [Abstract] [Full Text] [Related]

  • 17. Predictive value of soluble haemoglobin scavenger receptor CD163 serum levels for survival in verified tuberculosis patients.
    Knudsen TB, Gustafson P, Kronborg G, Kristiansen TB, Moestrup SK, Nielsen JO, Gomes V, Aaby P, Lisse I, Møller HJ, Eugen-Olsen J.
    Clin Microbiol Infect; 2005 Sep 04; 11(9):730-5. PubMed ID: 16104988
    [Abstract] [Full Text] [Related]

  • 18. Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163.
    Møller HJ, Moestrup SK, Weis N, Wejse C, Nielsen H, Pedersen SS, Attermann J, Nexø E, Kronborg G.
    Crit Care Med; 2006 Oct 04; 34(10):2561-6. PubMed ID: 16915112
    [Abstract] [Full Text] [Related]

  • 19. Association of serum adiponectin with risk for cardiovascular events in patients with peripheral arterial disease.
    Urbonaviciene G, Frystyk J, Flyvbjerg A, Henneberg EW, Lindholt JS.
    Atherosclerosis; 2010 Jun 04; 210(2):619-24. PubMed ID: 20096841
    [Abstract] [Full Text] [Related]

  • 20. Role of the tumour necrosis factor-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14 (Fn14) axis in autoimmune thyroid disease.
    Peng S, Yu X, Zhao X, Wang X, Sun X, Han C, Shan Z, Li C, Teng W.
    Clin Endocrinol (Oxf); 2017 Dec 04; 87(6):783-790. PubMed ID: 28636775
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.